newsfilter
← Latest News
Business Wire·

Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer's Disease

ZUNVEYL is the first oral FDA-approved treatment for Alzheimer's disease in the past decade 32 person sales team hired to cover the $2 billion Long-Term-Care market All launch activities delivered on-time and